Abstract
A novel dipyrazole ethandiamide compound and acid chloride of pyrazolo[3,4-d]pyrimidine 4(5H)-one were prepared and reacted with a number of nucleophiles. The resultant novel compounds were tested in several in vitro and in vivo assays. Three compounds inhibited the secretion of neurotoxins by human THP-1 monocytic cells at concentrations that were not toxic to these cells. They also partially inhibited both cyclooxygenase-1 and -2 isoforms. In animal studies, two compounds were notable for their anti-inflammatory activity that was comparable to that of the clinically available cyclooxygenase-2 inhibitor celecoxib. Modeling studies by using the molecular operating environment module showed comparable docking scores for the two enantiomers docked in the active site of cyclooxygenase-2. © 2010 Elsevier Ltd.
Author supplied keywords
Cite
CITATION STYLE
Youssef, A. M., Neeland, E. G., Villanueva, E. B., White, M. S., El-Ashmawy, I. M., Patrick, B., … Abd-El-Aziz, A. S. (2010). Synthesis and biological evaluation of novel pyrazole compounds. Bioorganic and Medicinal Chemistry, 18(15), 5685–5696. https://doi.org/10.1016/j.bmc.2010.06.018
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.